Media stories about Vical (NASDAQ:VICL) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Vical earned a news sentiment score of 0.24 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.0447604692053 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

A number of equities research analysts have commented on VICL shares. ValuEngine lowered Vical from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Zacks Investment Research lowered Vical from a “hold” rating to a “sell” rating in a research report on Thursday, October 26th. Finally, HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Vical in a research report on Tuesday, November 21st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $7.50.

Shares of Vical (NASDAQ VICL) traded down $0.03 during midday trading on Wednesday, reaching $1.83. The company’s stock had a trading volume of 106,300 shares, compared to its average volume of 173,020. Vical has a 12-month low of $1.66 and a 12-month high of $3.70.

Vical (NASDAQ:VICL) last announced its quarterly earnings data on Monday, October 23rd. The biotechnology company reported ($0.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.02). Vical had a negative return on equity of 29.06% and a negative net margin of 92.13%. The business had revenue of $3.24 million for the quarter, compared to analyst estimates of $3.60 million. equities analysts predict that Vical will post -1 earnings per share for the current fiscal year.

In other news, Director Robert C. Merton purchased 85,700 shares of the business’s stock in a transaction dated Friday, November 10th. The stock was bought at an average cost of $1.75 per share, with a total value of $149,975.00. Following the purchase, the director now directly owns 95,451 shares of the company’s stock, valued at $167,039.25. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 5.88% of the company’s stock.

WARNING: “Vical (VICL) Earns Daily Media Sentiment Rating of 0.24” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/20/vical-vicl-earns-daily-media-sentiment-rating-of-0-24.html.

About Vical

Insider Buying and Selling by Quarter for Vical (NASDAQ:VICL)

Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.